EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study

Qinghai Fu, Xiaolong Wang, Shiqin Zheng, Wei Wang

American Journal of Cancer Research · 2026 · 16 (6) · 2503-2517

DOI: 10.62347/dccq4239 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Qinghai Fu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomabiomarkerlenvatinibprognosispropensity score matchingsalt-inducible kinase 2sorafenib

Autor:innen und Institutionen

  • Department of Gastroenterology, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.
  • Department of Gastrointestinal Surgery, Sinopharm Dongfeng General Hospital Shiyan 442008, Hubei, China.

Zitieren

APA

Fu, Q., Wang, X., Zheng, S., & Wang, W. (2026). Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research, 16(6), 2503-2517. https://doi.org/10.62347/dccq4239

Vancouver

Fu Q, Wang X, Zheng S, Wang W. Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study. American Journal of Cancer Research. 2026;16(6):2503-2517. doi:10.62347/dccq4239

BibTeX
@article{Fu2026,
  author = {Fu, Qinghai and Wang, Xiaolong and Zheng, Shiqin and Wang, Wei},
  title = {Prognostic value of salt-inducible kinase 2 expression in advanced hepatocellular carcinoma treated with sorafenib or lenvatinib: a propensity score-matched cohort study},
  journal = {American Journal of Cancer Research},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {2503--2517},
  doi = {10.62347/dccq4239}
}
Kostenlos starten →